Navigation

Penn Herb Wellness Guide

Celecoxib

Common brand names:

Celebrex

Celecoxib is used to treat rheumatoid arthritis and osteoarthritis; it is in a class of medications known as selective COX-2 inhibitor non-steroidal anti-inflammatory drugs (NSAIDs).

Summary of Interactions with Vitamins, Herbs, & Foods

What Are Nutrient Interactions
Types of interactions:beneficial= Beneficialadverse= Adversecheck= Check
dnicon_BeneficialReplenish Depleted Nutrients
Iron
dnicon_BeneficialReduce Side Effects
Licorice
dnicon_BeneficialSupport Medicine
Stinging Nettle
dnicon_AvoidReduces Effectiveness

none

dnicon_AvoidPotential Negative Interaction
Sodium
White Willow
dnicon_CheckExplanation Required
Potassium
The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers’ package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a new supplement with your doctor or pharmacist.

Copyright 2025 TraceGains, Inc. All rights reserved.

RxAnswers is a copyrighted product from TraceGains.

This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.

There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer.

Learn more about TraceGains, the company.

Learn more about the authors of RxAnswers.

TraceGains and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.

Information expires December 2025.